Field Trip Discovery

Field Trip Discovery Image

About Field Trip Discovery

In order to bring the world to life through psychedelics, new psychedelic products and medicines will be needed to reach broader populations and treat a wider array of conditions. Field Trip Discovery, our R&D division, was created to do just that: research, develop and eventually commercialize psychedelic-inspired regulated products and medicines.

Next Generation Psychedelic Medicines

Field Trip Discovery’s primary focus is in developing novel, patented, regulated medicines targeting the serotonin 5HT2A serotonin receptor, which is believed to be the primary receptor involved in psychedelic experiences and responsible for the use of these substances to treat mental disorders, including depression and anxiety.

Discovery’s first molecule in development, FT-104, is a synthetic psychedelic molecule for which anecdotal information indicates unique and useful pharmacological features that could make FT-104 a more commercially viable alternative to naturally-derived substances, such as DMT, 5-MeO-DMT, psilocybin and LSD. The pharmacological activity of FT-104 has been confirmed and it is currently in preclinical evaluation. Field Trip anticipates initial Phase 1 clinical studies in 2021. A provisional patent relating to FT-104 composition and use has been filed with the USPTO (63,045,901; June 30, 2020).

Advanced Research on Psilocybin-Producing Fungi

Field Trip Discovery also conducts research and development related to the cultivation of psilocybin-producing mushrooms, as well as the identification, isolation and characterization of active substances contained in mushrooms and related fungi. Botanical materials are complex and diverse, and may contain many substances that modify the psychedelic experience by direct and indirect actions at serotonin, dopamine and other receptors, as well as within the cellular transport and accumulation mechanisms in the brain.

Discovery’s botanical research is conducted in collaboration with the University of West Indies (UWI), headed by Dr. Rupika Delgoda, Executive Director of the Natural Products Institute at UWI. While Field Trip initiated cultivation studies as early as Dec 2019, a state-of-the-art facility was outfitted on UWI’s Mona campus to expand FT’s research capacity.

Expert Team

FT Discovery is led by Dr. Nathan Bryson, the Issuer’s Chief Science Officer. Dr. Bryson, who holds a PhD in Chemistry and a Postdoctoral Associate Degree from the Massachusetts Institute of Technology, has three decades of hands-on research and development experience in the biotechnology and pharmaceutical industries, where he has overseen innovation, clinical development, regulatory, quality, global supply chain and medical affairs.

Nathan is supported by external scientific advisors that include Dr. Michael Ehlers (Partner at Apple Tree Partners, former Senior Vice President, Neurosciences at Pfizer and former Executive Vice President at Biogen), Dieter Weinand (former Chairman and CEO of Bayer Pharmaceuticals AG), Dr. Sidney Kennedy (Professor of Psychiatry, University of Toronto) and Dr. Matt Johnson (Professor in Psychology at Johns Hopkins School of Medicine and at Center for Psychedelic Research).


Portrait
Dr. Nathan BrysonChief Scientific Officer

Dr. Bryson joins Field Trip after serving as Chief Scientific Officer at Cynapsus Therapeutics and at Acerus Pharmaceuticals. He brings more than 25 years of experience in various aspects of pharmaceutical development from early-stage drug delivery design and development through to regulatory affairs for market approval and medical affairs support for sales. Dr. Bryson holds a BSc in Chemistry from Auburn University and a PhD in Radiopharmaceutical Chemistry from the Massachusetts Institute of Technology (“MIT”). He performed post-doctoral research under two well-esteemed chemists, the late Dr. John Osborn at the University Louis Pasteur (Strasbourg, France) and Dr. Dietmar Seyferth at MIT.

Portrait
Dr. Michael EhlersAdvisor

Dr. Michael Ehlers has more than 20 years of experience in biopharmaceutical leadership and biomedical research. Currently CEO of Limelight Bio and CSO of Apple Tree Partners, Dr. Ehlers was previously Executive Vice President and Head of Research & Development at Biogen, one of the world’s oldest and largest biopharmaceutical companies. Prior to that, Dr. Ehlers was Senior Vice President of BioTherapeutics R&D and the Chief Scientific Officer for Neuroscience & Pain at Pfizer. He holds a BS in chemistry from the California Institute of Technology, and M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine.

Portrait
Dieter WeinandBoard Member

Mr. Weinand is the former President, CEO and Chairman of the Board of Bayer Pharmaceuticals, AG and has 30 years of experience in senior executive roles with a number of pharmaceutical companies, including Sanofi, Otzuka and Pfizer. He has a demonstrated ability to recognize opportunity, create a vision and strategy, and mobilize organizations behind successful execution. Mr. Weinand has launched and marketed some of the industry’s most successful products, including Lipitor, Neurontin, Abilify, and Cipro.

Portrait
Dr. Sidney KennedyAdvisor

Dr. Sidney H. Kennedy is Professor of Psychiatry at the University of Toronto, the Arthur Sommer Rotenberg Chair in Suicide and Depression Studies, and a Scientist at Li Ka Shing Knowledge Institute and Toronto Western Research Institute, Toronto, Canada. Dr. Kennedy is the lead investigator for a large depression biomarker initiative. He has published extensively on new drug evaluation, neuroimaging and neurostimulation therapies, personality factors in depression, antidepressant effects on sexual function and treatment guidelines for Major Depressive Disorder and Bipolar Disorder.Dr. Kennedy is the Immediate Past President of the International Society for Affective Disorders, former President of the Canadian College of Neuropsychopharmacology, and the founding chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT). He has published more than 350 peer reviewed publications and 11 books on depression and related topics.